Enveric Biosciences

09/22/2025

A new article from Honeysuckle Magazine details how neurostabilogens, a new class of molecules from Enveric, have the potential to capture the therapeutic benefits of psychedelics without the hallucinations to help reduce costs and clinical burdens. Enveric expects to submit its IND for its neurostabilogen EB-003 in early 2026.

Enveric Biosciences (NASDAQ: ENVB) is pioneering non-hallucinogenic therapies called neurostabilogens. With FDA guidance fast-tracking its lead candidate EB-003, Enveric is positioning itself as a scalable, practical alternative to first-wave psychedelic treatments.

09/19/2025

Enveric Biosciences has announced the closing of exercise of warrants for $2.2 million gross proceeds. Details: https://bit.ly/4nC6gw7

09/18/2025

Enveric is developing a differentiated class of non-hallucinogenic neuroplastogens that have the potential to make psychedelic-like benefits practical, scalable, and clinically accessible. Microdose highlights the Company's regulatory progress, including its streamlined plans for EB-003 IND submission which is expected in early 2026.

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been viewed as a fringe pursuit, scientifically intriguing, but clinically and commercially fraught....

09/18/2025

Joseph Tucker, Ph.D. comments on the publication of two peer-reviewed articles which highlight Enveric's novel bioproduction methods for neuropsychiatric drug discovery. For more information, visit: https://bit.ly/3VlRVrG

09/17/2025

Enveric's second paper, published in BioDesign Research, reports the first bioproduction method for M**A and related compounds. Find details here: https://bit.ly/3VlRVrG

09/17/2025

Enveric CEO Dr. Joseph Tucker comments on the written response from the FDA to the Company's request for a pre-IND Type B meeting for its lead program, EB-003. For more information, visit: https://bit.ly/47H9utD

09/17/2025

Enveric Biosciences has announced the exercise of warrants for $2.2 million gross proceeds. Details: https://bit.ly/4pzrZGX

09/17/2025

Enveric's first paper, published in ACS Chemical Biology, describes how researchers engineered microbial systems to produce a wide range of indolethylamine derivatives relevant to neuroplastogen drug discovery. More info: https://bit.ly/3VlRVrG

09/17/2025

Enveric has announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds. The research, published in ACS Chemical Biology and BioDesign Research, describes new approaches for producing tryptamine and M**A-derived compounds. Learn more: https://bit.ly/3VlRVrG

09/16/2025

Following the FDA's written response, Enveric will streamline its regulatory path by advancing toward the submission of its IND application for EB-003. Enveric expects to file an IND application for EB-003 in early 2026. https://bit.ly/47H9utD

09/16/2025

Enveric has received a written response from the U.S. FDA to its request for a pre-IND Type B meeting for its lead program, EB-003. In its response, the FDA indicated that the questions for the pre-IND meeting proposed by Enveric were a matter for IND application review and recommended that Enveric proceed to submitting its IND application and protocol for review. Enveric interprets this outcome as consistent with the view that the Company is sufficiently advanced in its development strategy to proceed past the pre-IND meeting milestone. More info: https://bit.ly/47H9utD

09/07/2025

Tomorrow at 7:00am ET, Enveric's CEO Joseph Tucker, Ph.D. will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference. Register to watch here: https://bit.ly/3gk8b7C